Our Parkinson's Place: Parkinson's Disease Treatment Soon to Be Discontinued

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Saturday, December 22, 2018

Parkinson's Disease Treatment Soon to Be Discontinued

December 20, 2018 Da Hee Han, PharmD

The Food and Drug Administration (FDA) has posted a discontinuation notice for Requip (ropinirole HCl; GlaxoSmithKline) tablets and certain Requip XL (ropinirole HCl; GlaxoSmithKline) extended-release tablets.

Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson's disease.

The affected products include Requip 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, and 5mg strength tablets in 100-count bottles, and Requip XL 2mg strength tablets in 30-count bottles. The anticipated final dates of availability to patients are as follows:

Requip 0.25mg (NDC 0007-4890-20): April 2019
Requip 0.5mg (NDC 0007-4891-20): May 2019
Requip 1mg (NDC 0007-4892-20): January 2019
Requip 2mg (NDC 0007-4893-20): January 2019
Requip 3mg (NDC 0007-4895-20): April 2019
Requip 4mg (NDC 0007-4896-20): May 2019
Requip 5mg (NDC 0007-4894-20): March 2019
Requip XL 2mg (NDC 0007-4885-13): March 2019

The discontinuation of these products was a business decision, according to the FDA notice. Requip XL is still available as 4mg, 6mg, 8mg, and 12mg extended-release tablets.

For more information call (908) 293-5330 or visit FDA.gov.